ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 22

Expression of High Mobility Group Box 1 Protein and the Receptor for Advanced Glycation End Products in Primary Gouty Arthritis

Yu-Feng Qing1, Quan-Bo Zhang2, Shu-Yue Pan3 and Jingguo Zhou4, 1Affiliated Hospital of North Sichuan Medical College, Sichuan 637000, China, Nanchong, China, 2Department of geriatrics of the Affiliated Hospital of North Sichuan Medical College, Sichuan 637007, China, Nachong, China, 3Department of Rheumatology and Immunology of the Affiliated Hospital of North Sichuan Medical College, Sichuan 637000, China, Nachong, China, 4Department of Rheumatology and Immunology, Affliated hospital of North Sichuan Medical College, Nanchong, China

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Gout and pathogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

To investigate the role of high mobility group box 1 protein (HMGB1)  and the receptor for advanced glycation end products (RAGE) in the pathogenesis of primary gouty arthritis (GA).

Methods:

(1) Enzyme-linked immunosorbent assay(ELISA) was used to determine the level of plasma HMGB1 in 68 acute gout (AG), 48 intercritical gout (IG) and 45 healthy control (HC). (2)Real-time quantitative polymerase chain reaction (RT-qPCR) was employed to study the expression of HMGB1 and RAGE mRNA in peripheral blood mononuclear cells (PBMCs) in 68 AG,48 IG and 94 HC, and the differences of gene expression in two groups were compared .(3)Western blot(WB)was used to measure HMGB1 in PBMCs from 18 AG, 13 IG and 21 HC,REGE in PBMCs from 12 GA and 8 HC, and the otherness of protein expression in two groups were compared .(4)Analysis of T test or Wilcoxon test and Spearman’s correlations were used for statistical analysis.

Results:

The level of plasma HMGB1, PBMCs HMGB1, RAGE mRNA and protein were significantly higher in GA patients than those in HC (plasma HMGB1 (ng/mL): 222.00±178.32 vs 106.99±175.79 vs 23.88±34.05; PBMCs HMGB1 mRNA: 0.235±0.954 vs 0.044±0.117 vs 0.019±0.029; PBMCs RAGE mRAN�F0.0015±0.0035 vs 0.0013±0.0009 vs 0.0005±0.0003; HMGB1 protein:3.59±2.49 vs 1.89±2.00 vs 0.74±0.78�GP<0.05)),while the level of plasma HMGB1 and PBMCs HMGB1 mRNA were significantly higher in AG patients than those in IG  patients (P<0.05), the level of PBMCs RAGE protein was higher in GA patients than that in HC (2.94±0.67 vs 1.61±0.51; P<0.05), and the level of PBMCs RAGE mRNA was higher in AG patients than that in IG patients (P>0.05) . In the GA patients, the level of plasma HMGB1 was positively correlated with white blood cell, neutrophile granulocyte, mononuclear cell and erythrocyte sedimentation rate (r=0.34,0.44,0.39,0.33; P<0.05),while negatively correlated with apolipoprotein A1(r=-0.28; P<0.05); the level of PBMCs HMGB1 mRNA was positively correlated with RAGE mRNA, white blood cell counts, neutrophil counts, lymphocyte counts, total cholesterol, low density lipoprotein and apolipoprotein B100 (r=0.29,0.36,0.26,0.28,0.29; P<0.05),while negatively correlated with high density lipoprotein (r=-0.30;P <0.01); the level of PBMCs RAGE mRNA was positively correlated with Lymphocyte counts, total cholesterol and apolipoprotein B100 (r=0.35,0.35,0.44; P<0.05).

Conclusion:

HMGB1 and its signaling pathway might play an important role in the pathogenesis of gouty arthritis, which may also be involved in regulating the lipid metabolism of gout.


Disclosure: Y. F. Qing, None; Q. B. Zhang, None; S. Y. Pan, None; J. Zhou, None.

To cite this abstract in AMA style:

Qing YF, Zhang QB, Pan SY, Zhou J. Expression of High Mobility Group Box 1 Protein and the Receptor for Advanced Glycation End Products in Primary Gouty Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/expression-of-high-mobility-group-box-1-protein-and-the-receptor-for-advanced-glycation-end-products-in-primary-gouty-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expression-of-high-mobility-group-box-1-protein-and-the-receptor-for-advanced-glycation-end-products-in-primary-gouty-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology